Edwards Lifesciences Corp（EW）の決算・業績分析
Edwards Lifesciences Corpの2025年有価証券報告書をAI分析。売上高$6.1B(+11.5%)。営業利益$1.3B。Health Care。
目次
Edwards Lifesciences Corpの2025年度 業績サマリー
Edwards Lifesciences Corp（証券コード: EW）の2025年度決算・業績分析。売上高は$6.1B（前年比+11.5%）。営業利益は$1.3B（前年比-8.3%）。純利益は$1.1B（前年比-74.3%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
Edwards Lifesciences Corpの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue declined 14.7% YoY to $4.5B (XBRL), driven by the sale of the Critical Care product group (10-K).
- Net income rose 1.3% YoY to $1.5B (XBRL), despite operating income falling 11.4% YoY (XBRL).
- Net debt was -$535M (-0.3x EBITDA) (XBRL), reflecting strong liquidity and low leverage.
- R&D investment reached $844M (XBRL), representing 19% of net sales (10-K).
Edwards Lifesciences Corpの売上高変化の要因
- •Total revenue declined 14.7% YoY to $4.5B (XBRL), with operating income falling 11.4% YoY to $1.5B (XBRL). The decline was partially offset by growth in TAVR and TMTT products (10-K). Segment-specific revenue data is not available in XBRL (N/A). Historical time series show revenue peaked at $5.2B in FY2023 before declining to $4.5B in FY2024 (XBRL).
Edwards Lifesciences Corpの営業利益変化の要因
- •Gross profit remained strong at $3.7B (83.8% margin) (XBRL), though gross margin declined due to foreign currency exchange rate fluctuations (10-K). Operating margin fell to 33.6% (from 38.1% in FY2023) (XBRL), likely impacted by the sale of the Critical Care product group (10-K). Net margin held at 34.1% (XBRL), with net income rising 1.3% YoY to $1.5B (XBRL).
Edwards Lifesciences Corpの事業リスクと対応
Failure to innovate could render existing products obsolete (10-K).
Unsuccessful clinical trials may delay regulatory approvals (10-K).
Manufacturing or quality issues could disrupt operations (10-K).
Reliance on key physicians/hospital systems creates vulnerability (10-K).
Intense competition risks losing market share to newer technologies (10-K).
Regulatory risks include product liability claims and compliance with data privacy laws (10-K).
Edwards Lifesciences Corpの今後の見通し・業績予想
Edwards Lifesciences Corpの事業内容
Edwards Lifesciences is a global leader in structural heart innovation, specializing in heart valve replacement and repair solutions through surgical and transcatheter therapies (10-K). Key products include Transcatheter Aortic Valve Replacement (TAVR) systems like the SAPIEN 3 platform, Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart solutions (10-K). The company's competitive advantages include leadership in transcatheter valve technologies, robust clinical evidence, and a broad portfolio of repair/replacement solutions (10-K).
Edwards Lifesciences CorpのAI業績分析レポート（2024年度）
Edwards Lifesciences Corp (EW) FY2024 Annual Report Analysis
Highlights
Business Overview
Edwards Lifesciences is a global leader in structural heart innovation, specializing in heart valve replacement and repair solutions through surgical and transcatheter therapies (10-K). Key products include Transcatheter Aortic Valve Replacement (TAVR) systems like the SAPIEN 3 platform, Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart solutions (10-K). The company's competitive advantages include leadership in transcatheter valve technologies, robust clinical evidence, and a broad portfolio of repair/replacement solutions (10-K).
Revenue Analysis
Total revenue declined 14.7% YoY to $4.5B (XBRL), with operating income falling 11.4% YoY to $1.5B (XBRL). The decline was partially offset by growth in TAVR and TMTT products (10-K). Segment-specific revenue data is not available in XBRL (N/A). Historical time series show revenue peaked at $5.2B in FY2023 before declining to $4.5B in FY2024 (XBRL).
Profitability Analysis
Gross profit remained strong at $3.7B (83.8% margin) (XBRL), though gross margin declined due to foreign currency exchange rate fluctuations (10-K). Operating margin fell to 33.6% (from 38.1% in FY2023) (XBRL), likely impacted by the sale of the Critical Care product group (10-K). Net margin held at 34.1% (XBRL), with net income rising 1.3% YoY to $1.5B (XBRL).
Balance Sheet Analysis
Equity rose to $6.7B (XBRL), with an equity ratio of 71.0% (XBRL). Long-term debt was $597M (XBRL), resulting in net debt of -$535M (-0.3x EBITDA) (XBRL). Current ratio was 3.38x (XBRL), indicating strong short-term liquidity. Total assets grew to $9.4B (XBRL), with total equity increasing from $3.0B in FY2020 to $6.7B in FY2024 (XBRL).
Cash Flow Analysis
Operating cash flow was $1.2B (XBRL), with free cash flow of $974M (XBRL) after $245M in CapEx (XBRL). Share repurchases totaled $1.7B (XBRL), while financing activities showed a net outflow of $1.6B (XBRL). Historical operating cash flow peaked at $1.7B in FY2023 before declining to $1.2B in FY2024 (XBRL).
Working Capital Analysis
Cash conversion cycle (CCC) was 425 days (XBRL), with receivables days at 63 days (XBRL), inventory days at 456 days (XBRL), and payables days at 94 days (XBRL).
Risks
Outlook
Management highlights growth in TAVR/TMTT, the sale of Critical Care, and R&D investment (19% of net sales) as key trends impacting future results (10-K). No explicit forward-looking guidance is provided for FY2025 (10-K).
Historical Time Series
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | 3.7B | 4.3B | 4.4B | 5.2B | 4.5B | 5.0B |
| Operating Income | 748M | 1.1B | 898M | 1.7B | 1.5B | 1.3B |
| Net Income | N/A | N/A | N/A | 1.5B | 1.5B | 1.4B |
| Total Assets | 6.5B | 7.2B | 8.5B | 8.3B | 9.4B | 13.1B |
| Total Equity | 3.0B | 3.1B | 4.1B | 5.8B | 6.7B | 10.0B |
| Operating Cash Flow | 927M | 1.2B | 1.1B | 1.7B | 1.2B | 896M |
Health Careの企業一覧
Edwards Lifesciences Corpと同じ「Health Care」セクターの企業